Enedra Therapeutics
Discovering precision therapies targeting chromosomal instability to treat genetically heterogeneous cancers using computational genomics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | Debt | |
| Total Funding | 000k | ||
Related Content
Enedra Therapeutics is a biotechnology company focused on developing precision medicines to treat cancers characterised by chromosomal instability. This genomic abnormality, common in later-stage cancers, contributes to drug resistance, metastasis, and immune evasion. The company’s research aims to identify and validate drug targets that are essential for the survival of tumour cells with high chromosomal instability, enabling the design of treatments effective against biologically complex and heterogeneous cancers.
The company uses an internal computational platform that combines advanced genomics and multi-omic analysis to identify vulnerabilities in cancer cells. This platform supports the selection of therapeutic targets and the development of biomarkers to guide patient stratification, ensuring that treatments are tailored to specific molecular profiles. By integrating computational biology with oncology drug discovery, Enedra seeks to address cancers that have traditionally been difficult to treat due to their genetic diversity and adaptability.
Founded in 2021 in Cambridge, United Kingdom, Enedra emerged with the backing of the Cancer Research Horizons entrepreneurship programme and Deep Science Ventures. In 2024, the Centre for Drug Design and Discovery (CD3) joined as a partner, providing expertise and resources to support the identification and validation of novel targets. The company’s long-term goal is to advance its drug candidates from discovery into clinical development and eventual commercialisation, manufacturing its own therapeutics for oncology patients.
Enedra’s leadership and advisory teams bring together expertise in medicinal chemistry, computational biology, pharmaceutical research and development, and business operations. Their combined skills support a multidisciplinary approach that bridges computational sciences and experimental validation in the pursuit of effective cancer treatments.
Keywords: precision medicines, chromosomal instability, heterogeneous cancers, oncology therapeutics, drug discovery, computational biology, genomic science, multi-omic analysis, target identification,